Characteristic | Aleglitazar 150 μg (n = 149) | Pioglitazone 45 mg (n = 148) |
---|---|---|
Patient characteristics* | ||
Age, years | 66. 8 ± 8.0 | 68.2 ± 7.6 |
Women, n (%) | 74 (50) | 78 (53) |
Race, white, n (%) | 129 (87) | 120 (81) |
BMI, kg/m2 | 29.8 ± 3.3 | 29.8 ± 3.1 |
Median duration of diabetes, years | 9.6 (0.4–40.2) | 10.2 (0.2–48.2) |
Systolic blood pressure, mmHg | 130.5 ± 8.3 | 132.1 ± 10.4 |
Diastolic blood pressure, mmHg | 77.6 ± 7.1 | 76.6 ± 8.7 |
Smokers, n (%) | 8 (5) | 4 (3) |
Laboratory data* | ||
HbA1c, % | 7.5 ± 0.9 | 7.6 ± 0.9 |
FPG, mmol/L | 8.5 ± 2.3 | 8.7 ± 2.2 |
Triglycerides, mmol/L | 2.3 ± 1.6 | 2.2 ± 1.2 |
HDL-C, mmol/L | 1.2 ± 0.3 | 1.2 ± 0.3 |
LDL-C, mmol/L | 2.7 (2.1–3.4) | 2.9 (2.3–3.5) |
Markers of renal function | ||
eGFR, mL/min/1.73 m2 | 46.5 ± 10.2 | 46.7 ± 10.2 |
SCr, μmol/L | 123.6 ± 30.5 | 121.4 ± 29.2 |
Cystatin-C, μg/mL | 1.2 ± 0.4 | 1.2 ± 0.3 |
UACR, mg/mmol† | 2.0 (0.27–257.97) | 1.9 (0.24–551.33) |
Markers of RAAS | ||
Renin, pmol/L | 34.4 (17.8–130.5) | 27.0 (17.8–87.0) |
Aldosterone, pmol/L | 194.2 (111.0–332.9) | 194.2 (111.0–305.1) |
Sodium excretion (fractional), % | 1.5 (1.0–1.9) | 1.5 (1.1–2.1) |
Renal tubular markers | ||
α-GST, μg/L | 3.1 (3.1–3.1) | 3.1 (3.1–3.9) |
NAG, U/L | 2.9 (1.6–4.7) | 3.2 (1.8–5.1) |
Baseline medication use, n (%) | ||
Glycemic control treatment | ||
Drug-naïve | 6 (4) | 7 (5) |
Oral antidiabetic agents | 143 (96) | 141 (95) |
Sulfonylurea | 112 (75) | 112 (76) |
Metformin | 87 (58) | 95 (64) |
Antihypertensive medication | 138 (93) | 140 (95) |
Diuretics | 73 (49) | 81 (55) |
ACE inhibitors and/or ARB | 120 (81) | 121 (82) |
Statins | 78 (52) | 68 (46) |
Aspirins‡§ | 65 (44) | 64 (43) |